Shares of Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) got a boost, shooting up 63 percent to $2.38 after the company announced Thursday the release of a 99-cent alternative to Allergan PLC (NYSE: AGN)'s Restasis to address the 30 million Americans suffering from Dry Eye Disease.